ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTBO Cantabio Pharmaceuticals Inc (CE)

1.01
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cantabio Pharmaceuticals Inc (CE) USOTC:CTBO OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.01 0.00 01:00:00

Notification That Annual Report Will Be Submitted Late (nt 10-k)

30/06/2016 6:17pm

Edgar (US Regulatory)


 
 


U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 12B-25
NOTIFICATION OF LATE FILING
SEC File Number 000-53232

Form 10-K

For Period Ending: March 31, 2016
  
PART I: REGISTRANT INFORMATION

Full Name of Registrant:  Cantabio Pharmaceuticals Inc.
  
Address of Principal Executive Office:
1250 Oakmead Pkwy
Sunnyvale, CA 94085-4037
(408) 501-8893
 
  PART II: RULES 12B-25(B) AND (C)
 
It is anticipated that the subject Annual Report on Form 10-K will be filed within the next several days.
 
  PART III: NARRATIVE
 
The Registrant has not completed its Annual Report on Form 10-K for the period ended March 31, 2016 due to administrative delays.
 
PART IV: OTHER INFORMATION
 
(1) Name and telephone number of person(s) to contact in regard to this notification
 
Thomas Roger Sawyer: (408) 501-8893
 
(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
 
[X] YES [ ] NO
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
[ ] YES [X] NO
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
 

 
 
 
 
Cantabio Pharmaceuticals Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
  
 
Cantabio Pharmaceuticals Inc.
 
       
Dated: June 30, 2016
By:
/s/  Thomas Roger Sawyer
 
   
Thomas Roger Sawyer
 
   
Chief Executive Officer
 

 
 
 
 
 
 


1 Year Cantabio Pharmaceuticals (CE) Chart

1 Year Cantabio Pharmaceuticals (CE) Chart

1 Month Cantabio Pharmaceuticals (CE) Chart

1 Month Cantabio Pharmaceuticals (CE) Chart

Your Recent History